• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Amyris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRS

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Amyris in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for AMRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Amyris. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$3.10 ➝ $0.65Low
5/10/2023TD CowenDowngradeOutperform ➝ Market Perform$4.00 ➝ $1.25Low
4/28/2023Canaccord Genuity GroupInitiated CoverageBuy$1.50Low
4/26/2023Piper SandlerLower Target$1.50 ➝ $1.00Low
3/16/2023Piper SandlerLower Target$2.00 ➝ $1.50Low
3/16/2023HC WainwrightLower Target$22.00 ➝ $5.00Low
1/3/2023Piper SandlerLower Target$2.50 ➝ $2.00Low
11/10/2022CowenLower Target$13.00 ➝ $6.00Low
11/10/2022CowenLower Target$13.00 ➝ $6.00Low
11/10/2022JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
11/9/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
9/19/2022Piper SandlerBoost TargetNeutral$2.50 ➝ $4.00Low
8/10/2022Roth CapitalDowngradeBuy ➝ NeutralLow
6/24/2022JPMorgan Chase & Co.Initiated CoverageNeutralLow
5/25/2022Piper SandlerInitiated CoverageNeutral$2.50High
11/9/2021Roth CapitalLower TargetBuy$22.00 ➝ $15.00High
10/15/2021CowenInitiated Coverage$19.00Low
8/6/2021Roth CapitalLower TargetBuy$25.00 ➝ $22.00Low
8/6/2021OppenheimerBoost TargetOutperform$25.00 ➝ $26.00Low
8/6/2021HC WainwrightLower TargetBuy$35.00 ➝ $30.00Low
6/1/2021HSBCInitiated CoverageBuy$20.00Medium
3/4/2021Roth CapitalBoost TargetBuy$20.00 ➝ $33.00N/A
3/3/2021HC WainwrightBoost TargetBuy$11.00 ➝ $35.00High
2/26/2021Roth CapitalInitiated CoveragePositive ➝ Buy$20.00High
1/6/2021CowenUpgradeMarket Perform ➝ Outperform$9.00N/A
12/16/2020HC WainwrightReiterated RatingBuyHigh
11/25/2020Jefferies Financial GroupInitiated CoverageBuy$3.35High
11/25/2020CowenInitiated CoverageMarket Perform$5.00High
9/11/2020OppenheimerReiterated RatingBuy$9.00Low
7/27/2020OppenheimerReiterated RatingBuy$9.00High
6/5/2020OppenheimerInitiated CoverageBuy$9.00High
2/3/2020OppenheimerReiterated RatingBuyMedium
12/11/2019OppenheimerInitiated CoverageOutperform$8.00Low
10/11/2019HC WainwrightReiterated RatingBuy$11.00High
(Data available from 5/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Amyris logo
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.54
Low: $0.05
High: $1.17

52 Week Range

Now: N/A

Volume

46,746,000 shs

Average Volume

12,593,118 shs

Market Capitalization

$18.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Amyris?

The following Wall Street sell-side analysts have issued reports on Amyris in the last year:
View the latest analyst ratings for AMRS.

What is the current price target for Amyris?

0 Wall Street analysts have set twelve-month price targets for Amyris in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Amyris in the next year.
View the latest price targets for AMRS.

What is the current consensus analyst rating for Amyris?

Amyris currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMRS.

How do I contact Amyris' investor relations team?

Amyris' physical mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company's listed phone number is (510) 450-0761 and its investor relations email address is [email protected]. The official website for Amyris is amyris.com. Learn More about contacing Amyris investor relations.